Predictive Technology Group Inc (OTCMKTS:PRED) just announced that it and Atrin Pharmaceuticals LLC areentering into a collaboration agreement to develop molecular diagnostic toolsto facilitate improved selection of cancer patients who would most benefit fromtreatment with DNA Damage and Response (DDR) inhibitors, including Atrins andother small molecule ATR inhibitors.

According to the release, Atrinand Predictive will jointly utilize Predictive Laboratories state-of-the-artsequencing capabilities and genomics expertise to identify cancer patients withspecific molecular markers that predict the level of clinical response toAtrins, and other, targeted therapies. This is intended to improve patientoutcomes as well as improve Atrins ability to successfully progress itsproduct pipeline, and upon commercialization, improve on the treatments forwomen with cancer.

Predictive Technology GroupInc (OTCMKTS:PRED) promulgates itself as a company that, together with itssubsidiaries, develops and commercializes discoveries and technologies involvedin novel molecular diagnostic and pharmaceutical therapeutic/human cells,tissues, and human cellular and tissue-based products (HCT/Ps).

The company operates throughtwo segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics andTherapeutics. It offers ARTguide, a genetic diagnostic and prognostic test forwomen experiencing infertility as a result of endometriosis and other healthconcerns; and regenerative medicine products, including AmnioCyteT, AmnioCytePlusT, PolyCyteT, and CoreCyteT.

The company was formerly knownas Global Enterprises Group, Inc. and changed its name to Predictive TechnologyGroup, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005and is headquartered in Salt Lake City, Utah.

According to companymaterials, Predictive Technology Group aims to revolutionize patient carethrough predictive data analytics, novel gene-based diagnostics and companiontherapeutics through its subsidiaries Predictive Therapeutics, PredictiveBiotech, and Predictive Laboratories. These subsidiaries are focused onendometriosis, scoliosis, degenerative disc disease and human cell and tissueproducts. The subsidiaries use genetic and other information as cornerstones inthe development of new diagnostics that assess a persons risk of illness andtherapeutic products designed to identify, prevent and treat diseases moreeffectively.

Find out when $PRED reaches critical levels. Subscribe toOracleDispatch.com Right Now by entering your Email in the box below.

As noted above, PRED just announced that it and Atrin Pharmaceuticals LLC are entering into a collaboration agreement to develop molecular diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with DNA Damage and Response (DDR) inhibitors, including Atrins and other small molecule ATR inhibitors.

Weve witnessed 36% piled onfor shareholders of the listing during the trailing month. In addition, thename has witnessed a pop in interest, as transaction volume levels haverecently pushed 11% above the average volume levels in play in this stock overthe longer term.

We are very pleased to workwith Atrin Pharmaceuticals, a recognized leader in the development ofanti-cancer therapeutics targeting DDR, said Bradley Robinson, president andchief executive officer of Predictive Technology Group. We see an opportunityto develop a precision medicine approach to address unmet medical needs bycombining our state-of-the-art sequencing capabilities, genomics expertise andcompanion diagnostics with Atrins targeted therapeutics. This collaboration isconsistent with our vision of building a leading womens health platform, andwe look forward to working together on this important initiative.

Currently trading at a marketcapitalization of $276M, PRED hasa chunk ($842K) of cash on the books, which stands against about $8.6M in totalcurrent liabilities. PRED is pulling in trailing 12-month revenues of $43.7M.In addition, the company is seeing major top-line growth, with y/y quarterlyrevenues growing at 2.4%. You can bet we will update this one again as newinformation comes into view. Sign-up forcontinuing coverage on shares of $PRED stock, as well as other hot stock picks,get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $PRED, either long orshort, and we have not been compensated for this article.

You have Successfully Subscribed!

Post Views: 175

Visit link:

Is Predictive Technology Group Inc (OTCMKTS:PRED) Ready for Another Run? - The Oracle Dispatch